Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss

C4 Therapeutics reported a Q3 GAAP EPS loss of –$0.44, missing estimates, but revenue of $11.23M beat expectations by $4.95M. CCCC's lead asset, cemsidomide, showed promising Phase 1 results in multiple myeloma and is advancing to pivotal Phase 2 and combination trials in 2026. Despite a net loss and heavy R&D spending, the company boasts a strong cash position and trades at a discount to sector peers, with limited pipeline premium.

Seeking Alpha • Nov 26, 2025

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference taking place from December 2 - 4, 2025 in Coral Gables, Florida.

GlobeNewsWire • Nov 25, 2025

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance. SiTime Corp. was also a top contributor. The company provides silicon timing chips for a wide range of electronics. The greatest detractor from Fund performance for the quarter was Monday.com Ltd.

Seeking Alpha • Nov 12, 2025

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 µg) and Differentiated Safety and Tolerability Profile  Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomide in Combination With Elranatamab On Track to Initiate Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 MOMENTUM Trial in Combination with Dexamethasone in Q1 2026 and Phase 1b Trial in Combination with Elranatamab in Q2 2026 WATERTOWN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the third quarter ended September 30, 2025, as well as business updates.

GlobeNewsWire • Nov 6, 2025

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to a loss of $0.35 per share a year ago.

Zacks Investment Research • Nov 6, 2025

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab

GlobeNewsWire • Oct 16, 2025

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody (BCMAxCD3 bispecific), to C4T for its upcoming Phase 1b trial.

GlobeNewsWire • Oct 1, 2025

C4 Therapeutics, Inc. - Special Call

C4 Therapeutics, Inc. - Special Call Company Participants Courtney Solberg - Senior Manager of Investor Relations Andrew Hirsch - CEO, President & Director Leonard M. J. Reyno - Chief Medical Officer Kendra Adams - CFO & Treasurer Conference Call Participants Sudan Loganathan - Stephens Inc., Research Division Binod Dhakal Bradley Canino - Guggenheim Securities, LLC, Research Division Etzer Darout - Barclays Bank PLC, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Yifan Xu - Jefferies LLC, Research Division Presentation Operator Good day, and welcome to the C4 Therapeutics' Phase I trial data of cemsidomide in multiple myeloma presented at IMS 2025 Conference Call.

Seeking Alpha • Sep 22, 2025

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population

GlobeNewsWire • Sep 20, 2025

Why C4 Therapeutics Stock Crushed the Market on Monday

C4 Therapeutics (CCCC 33.84%) was not only one of the better-performing healthcare stocks on Monday, it was one of the big winners on the market, period. The company seemed to have a rocket strapped to its back, as its share price blasted more than 34% higher after an analyst upgraded his recommendation.

The Motley Fool • Sep 15, 2025